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Abstract
Major depressive disorder (MDD) is a common psychiatric and behavioral disorder. To discover novel variants conferring risk
to MDD, we conducted a whole-genome scan of copy number variation (CNV), including 1,693 MDD cases and 4,506
controls genotyped on the Perlegen 600K platform. The most significant locus was observed on 5q35.1, harboring the SLIT3
gene (P=2610
23). Extending the controls with 30,000 subjects typed on the Illumina 550 k array, we found the CNV to
remain exclusive to MDD cases (P=3.2610
29). Duplication was observed in 5 unrelated MDD cases encompassing 646 kb
with highly similar breakpoints. SLIT3 is integral to repulsive axon guidance based on binding to Roundabout receptors.
Duplication of 5q35.1 is a highly penetrant variation accounting for 0.7% of the subset of 647 cases harboring large CNVs,
using a threshold of a minimum of 10 SNPs and 100 kb. This study leverages a large dataset of MDD cases and controls for
the analysis of CNVs with matched platform and ethnicity. SLIT3 duplication is a novel association which explains a definitive
proportion of the largely unknown etiology of MDD.
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Introduction
Major depressive disorder (MDD) is characterized by prolonged
sadness and is often observed in conjunction with poor perception
of self, frequent thoughts of suicide, lack of energy, and abnormal
sleep [1]. MDD results in significant social, work/school, and
overall health perturbation. The morbidity from depressive
perceptions and mortality from suicide attempt are substantial.
Genome-wide association studies (GWAS) have become a widely
adopted methodology to scan across many observed variations
known as single nucleotide polymorphisms (SNPs). Statistical
association of SNP genotypes for differences in frequencies
between population based case and control cohorts or family
based linkage and transmission disequilibrium tests have been
fruitful for a variety of disease phenotypes. However, psychiatric
disease GWAS studies have revealed relatively few robustly
associated and replicated loci [2,3], perhaps attesting to the more
complex heterogeneity underlying psychiatric disease phenotypes.
Genome-wide association studies of SNP genotype frequencies
in large MDD populations have revealed significance in PCLO [4],
ATP6V1B2 [5], SP4 [5], GRM7 [5], 3p21.1 [6], GLYATL1 [7], and
RYR3 [7]. While additional and independent replication studies
are awaited for some of these loci, it is noteworthy that these genes
support the disruption of neurotransmission networks of the brain
as the underlying cause of MDD. Genome-wide arrays provide
both SNP genotype and intensity data which we have evaluated in
tandem to assess the pattern and frequency of CNVs in a MDD
case control cohort. CNVs were called in each individual and
subsequently associated with the MDD phenotype, using a case
control study design, to discover the most common CNV in cases
which was exclusive when compared to a large control group.
Results
We processed genotype and intensity data for all 599,164 probes
of the Perlegen 600 K dataset for 3,761 MDD cases and controls,
1,682 Psoriasis cases and controls, and 2,788 ADHD trio samples
available through dbGaP. We first converted the Cartesian
coordinate values X and Y into Polar coordinates Theta and R
which correlate clearly to genotype and intensity values. The
observed values were then clustered to establish null expected
values for Theta and R for AA, AB, and BB states. Clustering was
successful on 586,730 probes. Values for B allele frequency (BAF)
and log R ratio (LRR) were then calculated for each SNP in each
sample based on this cluster. A HMM model was trained
specifically for the resulting data using PennCNV [8]. The
population allele frequency of each SNP was calculated to weigh
the probability of observing homozygote genotypes. The SNP
physical positions were given to weigh probability of extending
CNV calls vs. boundary truncation. Following QC for genotypes
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ethnicity outliers as described in Methods, we defined a clean data
set of 1,693 MDD cases and 1,697 controls at low probability for
MDD, 1,600 controls from a publically available psoriasis
case:control study in dbGaP, and 1,209 parents from a ADHD
parent-offspring project also in dbGaP. This gave us a total size of
1,693 MDD cases compared to 4,506 controls all typed on the
Perlegen 600 k array. The MDD case and controls that were at
low probability for MDD were clustered together yielding 97.9%
of SNPs with acceptable clustering. However, the samples were
not required to have high SNP call rate since duplications and
homozygous deletions can deviate from the three expected diploid
genotype modes in an informative manner. The psoriasis similarly
yielded 95.0% of SNPs usable while ADHD parents had 64.6%.
Therefore, the rates of exclusions for poor sample quality and
individual SNP quality were highly similar for cases and controls
with exception of the ADHD parents. The higher drop-out rate for
ADHD parents may represent a more unfiltered data release than
the other projects, more variability in sample quantity, less ability
to rerun failing samples, or other technical variability. Nonethe-
less, the MDD cases, MDD screened controls, and psoriasis
controls showed similar exclusion rates. Similarly, the genomic
inflation factor of the overall dataset was low showing that
variability from ancestral differences and technical artifacts were
minimal.
The Perlegen data has proven to have higher noise content than
comparable genome-wide SNP arrays from Illumina and Affyme-
trix. The essential chemistry problem which dilutes CNV signal in
Perlegen 600 k data is that PCR is run to the point of saturation.
Long-range PCR products are pooled together to facilitate probe
binding and boost signal for each SNP. However, as a result the
relative differences in intensity for different regions are diminished.
The problem is that many CNV calling algorithms use intensity
alone, rather than intensity and genotype in tandem as PennCNV
does. While there is a higher noise content to the data, we trained
a HMM specifically for this data and we have visually validated all
CNVs called by the Perlegen 600 K platform [9]. We also
observed inheritance of CNVs at loci across the genome which
boosted confidence in CNV calls.
We used PennCNV-Affy which evaluates intensity in terms of
Log R Ratio rather than Log 2 Ratio. The Log 2 Ratio is based on
quantile normalization, which derived from the sum of signal
intensity for A allele and B allele for each sample, the median
across all samples, and for a given sample, the A+B allele intensity
is divided by the median value and logarithm base 2 applied. In
contrast, the Log R Ratio is based on defined signal intensity
clusters of AA, AB and BB genotypes across a large group of
samples. Given this expected intensity value, the observed A+B
signal intensity data is divided by this expected value, and the
logarithm taken.
We evaluated the SNP-based frequency of deletions and
duplications between cases and controls to identify CNV regions
(CNVRs) common to cases and not observed in controls (Table 1).
We evaluated all 43,309 case and 89,744 control CNV calls
generated. We also evaluated only calls with at least 10 SNPs and
100 kb. The case and control cohorts lowered to 647 case and
1,590 control samples with 921 and 2,594 respective CNV calls
meeting this size condition. Certainly evaluating all called CNVs
regardless of size will introduce a substantial proportion of false
positive calls. However, comparison of resulting loci based on the
conservative filter and the all-inclusive filter is necessary to see if
any controls impact the locus with calls below the threshold. In this
way, the true exclusivity of case calls can be evaluated. We
evaluated all associated CNV regions recurrent in MDD cases and
exclusive with respect to controls (Table 1). Conversely, we did not
observe any CNV regions recurrent in controls not observed in
cases.
The CNV with the highest frequency in cases, exclusivity with
respect to controls, and with clear duplication signals was a locus
on 5q35.1 which impacts exons of SLIT3, CCDC99, and DOCK2
Table 1. All associated CNV regions recurrent in MDD cases.
CNV Region Count SNPs
Count MDD
Cases MDD Case IDs Gene(s)
chr5:168423758-169070607 198 5 05D01518 06D02197 06D06042
06D06073 06D11362
SLIT3,CCDC99,DOCK2
chr5:115261015-115369537 54 3 06D00054 07D00185 07D00852 AP3S1,AX747550,FLJ90650
chr5:25121416-25298271 18 3 06D03270 06D04240 06D05804 AK309747/CDH10*
chr4:65074807-68777792 273 2 05D00964 05D02984 EPHA5,CENPC1,STAP1,UBA6,GNRHR,TMPRSS11
chr15:97399748-97770838 95 2 06D01590 06D01080 SYMN, LRRC28,TTC23
chr10:81631178-81930681 68 2 05D02768 07D00173 SFTPD, C10orf57, PLAC9, ANXA11
chr8:21188347-21318056 64 2 05D02193 05D04794 AK057515/GFRA2**
chr7:17201925-17473214 62 2 06D02134 06D06089 AHR
chr7:8241584-8363438 42 2 05D03460 05D04353 ICA1,AX746880,CR624517
chr7:24922773-25040936 41 2 05D00474 06D00295 OSBPL3
chr1:239103312-239231293 35 2 05D01560 06D01602 RGS7
chr11:108105203-108301884 12 2 06D01991 07D00860 DDX10
Listed are all loci with CNVs of at least 10 SNPs and 100 kb that were observed to be recurrent among MDD patients and not found in any controls of substantial
overlap. All CNVs happened to be duplications and directly impact the genes indicated except
*CDH10 which is proximal 440 kb and involved in axon outgrowth and guidance and
**GFRA2 which is proximal 275 kb and involved in neuronal survival and differentiation. Note also ICA1 which is involved in neurotransmitter secretion. Given the PCR
saturation of Perlegen 600 K processing, it is fitting that the intensity signal is diminished. However, the genotype signal is very clear and duplication calls leverage the
AAB and ABB calls to deliver reliable calling. The observation of a run of homozygosity is quite common by chance so a lower intensity is important for deletion calls but
diluted in this case.
doi:10.1371/journal.pone.0015463.t001
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23). We ran permutation analysis through 10,000
simulations of case and controls to determine the probability of
such an observation by chance (P=2.7610
23). Depression cases
05D01518, 06D02197, 06D06042, 06D06073, and 06D11362
were clearly scored with large duplication CNVs. The calls were
near identical with coordinates on chr5 ranging from
168,423,758–169,070,607 shared by all 5 samples (Figure 1).
There were 198 SNP probe signals in agreement of the duplication
signal with SNP coverage nearby 59 and 39 breakpoints, providing
clear support for the CNV call and accurately capturing the
reproducible calling boundaries. The physical size is 646 kb which
was well above our conservative threshold of 100 kb. The SNP
based coordinates begin with rs4868223 and end with rs373808.
The PennCNV confidence score was high at 276. The large region
is very clear of any similar overlapping calls. The largest control
CNV in this region encompassed only 1.8 kb overlapping the
duplication observed in the depression cases. This low-confidence
CNV call encompasses less than 0.3% of the associated region and
does not impact genic exons and as such is an unimportant
variation. There are similarly small and non-exonic entries in the
Database of Genomic Variants (Figure 1). To evaluate the
exclusivity of this duplication further, we evaluated 30,000 patients
without neurological disorders typed on the Illumina 550 k
platform and did not observe the duplication in these additional
controls (P=3.2610
29).
To gain further confidence in the duplication calls on 5q35.1,
we extracted and viewed BAF and LRR values derived from the
Perlegen 600 k data for the CNV region and flanking diploid
regions (Figure 2). The BAF shows clear enrichment of values
ranging 0.3–0.4 (AAB genotype) and 0.6–0.7 (ABB genotype) in
the duplicated region. We observed an average of 83 SNPs
throughout the duplicated region in these ranges which are all
highly supportive of a duplication call. This clearly contrasts from
the normal diploid signals shown 59 and 39 for each sample with
many BAF signals ranging 0.4 to 0.6 (AB genotype). BAF values in
this range make the duplication call very clear for both a HMM
algorithm and a graphical review. The LRR data points are also
elevated in an overlapping supportive manner. The majority of
LRR signals are above the reference 0 expected diploid level and
values above 0.2 are enriched. The LRR was especially important
for sample 06D06042, which happened to have a large run of
homozygosity which encompassed the 39 end of the duplication
Figure 1. Duplication of 5q35.1 impacting SLIT3 observed in 5 unrelated MDD cases. The coverage of SNPs on the Perlegen 600 K array is
shown across the 5q35.1 locus with vertical blue lines. There are 198 SNPs within the duplication call boundaries shown as green rectangles for the 5
MDD cases with sample IDs listed to the left. Depression control, Psoriasis, and ADHD GAIN Perlegen 600 K sample sets are shown to not have CNV
calls of the large size observed in MDD cases. All calls generated are shown for completeness of observation. Very small calls of 1.8 kb and less are
observed in this region which is dissimilar from the case calls. The genes SLIT3, CCDC99, and DOCK2 are shown to have exons impacted by the
duplication. Finally, the Database of Genomic Variants entries are shown which are very small and do not impact exons.
doi:10.1371/journal.pone.0015463.g001
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Furthermore, the raw Cartesian SNP clusters, which represent
values completely unmodified by our methods, across the 5q35.1
region show clear AAB and ABB clusters (Figure 3). Although we
have done pairwise genotype comparisons as an upfront filter to
remove related individuals, we present the very low similarity
values between these 5 cases to show these are indeed independent
observations (Table 2). We also show these samples to be
representative of the Caucasian cohort studied (Figure 4).
Discussion
Our report represents the first genome wide association analysis
of CNVs in MDD. The study cohort consisted of 1,693 MDD
cases compared to 4,506 controls typed on the Perlegen 600 K
platform. The most significant locus included SLIT3, CCDC99,
and DOCK2 on 5q35.1. Duplication was observed in 5 unrelated
MDD cases encompassing 646 kb with highly similar breakpoints.
While the Perlegen 600 k array has been deemed to be an array
with data that is difficult to interpret CNV calling from, we have
established an approach, using the PennCNV-Affy methodology,
to robustly define the reference diploid state and extract not only
informative intensity data but also relative genotype content,
optimized HMM, and careful review of CNV calls, loci recurrently
impacted by CNVs, raw BAF and LRR values, and raw Cartesian
coordinates all support that these CNVs are real biological
phenomenon. We have experimentally validated a large number
of Perlegen-generated CNV calls with the independent method
qPCR and demonstrated their inheritance through families as a
further validation for the CNV calling [9]. The association of
5q35.1 and underlying CNV calls are robust as evidenced by the
nearly 200 SNP probes in agreement of duplication in these five
unrelated MDD samples.
We found that the first 4 exons of SLIT3 (slit homolog 3), the
entire CCDC99 gene and the first 15 exons of DOCK2 were
impacted by the duplication in all cases. Based on functional
classifications of these genes, SLIT3 is the strongest functional
candidate due to its role in axon development. SLIT3 is integral
to repulsive axon guidance based on binding to Roundabout
receptors. Slits are large, secreted repulsive axon guidance
molecules which function as ligands for Roundabout (Robo)
receptors. Slit3 has been characterized as an important player in
the genesis of the diaphragm and kidney. Slit3 promotes
angiogenesis, a process essential for proper organogenesis during
embryonic development [10]. Slits and Robo receptors have been
observed to be silenced in various cancer types, implicating its
role as a tumor suppressor. CCDC99 (coiled-coil domain
containing 99) was predicted to be a mitotic spindle protein,
suggested to be a human homologue of Drosophila Spindly, and
proven to localize at the spindle pole by immunofluorescence
microscopy [11]. DOCK2 (dedicator of cytokinesis 2) encodes a
protein specific to hematopoietic cells and is indispensable for
Figure 3. X and Y raw values showing common AA, AB, and BB states and rare AAB and ABB states. Raw Cartesian SNP Clusters with
duplicated depression cases colored in green. Duplication AAB and ABB calls are found on multiple SNPs across the 5q35.1 region.
doi:10.1371/journal.pone.0015463.g003
Figure 2. BAF and LRR SNP-based values for 5 MDD cases with Duplication of 5q35.1. The X axis represents the physical position on
chromosome 5 in MB. BAF and LRR are derived values representing genotype and intensity content from the theta and R values of the raw Cartesian
X and Y values provided directly by the Perlegen 600 K array. BAF and LRR values for 851 SNPs chromosome 5 ranging 167507516–169763949 are
displayed to provide a 59 and 39 frame of normal diploid genome surrounding the duplication CNV for each sample.
doi:10.1371/journal.pone.0015463.g002
Duplication of SLIT3 and Major Depressive Disorder
PLoS ONE | www.plosone.org 5 December 2010 | Volume 5 | Issue 12 | e15463lymphocyte migration by triggering cytoskeleton reorganization
via Rac activation [12]. Thus, the most robustly detected CNV
common to the most MDD cases and exclusive when compared
to a large control cohort typed on the same platform impacts
SLIT3, an axon guidance gene.
The controls collected within the MDD study (n=1,697) were
screened based on never scoring high (.0.65) on a general factor
score for anxious depression and never reported a history of MDD
in any survey, whereas the psoriasis (n=1,600) and ADHD
(n=1,209) control supplement lacked MDD screening in the
controls. Therefore, MDD cases could exist within the controls
where they could mask true association signals. Assuming the
population frequency of MDD at 16% [13], an estimated 449
subjects within the psoriasis and ADHD projects may have MDD
yielding up to 10% of the total control with MDD. These controls
were used nonetheless to provide the best matched genotyping
platform controls available.
We sought to evaluate the specific phenotypes of the 5 MDD
cases with the duplication of the SLIT3 locus. Although 77 clinical
parameters were available for these individuals, no clear bias for
specific co-morbidities was evident. The age of onset for
depression symptoms was 8, 16, 33, 30, and 30. Two were males
and three were females. Interestingly, the total scores for
Neuroticism Extraversion Openness (NEO) five-factor inventory
short form neuroticism were notably elevated at an average of 47
whereas the MDD population average was 34. Additional
characteristics including items from NEO, Inventory of Depres-
sion Severity (IDS) depression, and Beck Anxiety Inventory (BAI)
anxiety are included in Table S1.
We were unable to acquire the 5 samples to validate the presence
of the SLIT3 locus duplication with an independent technologysuch
as qPCR, FISH, or MLPA. Without this data, the possibility of false
positives exists, albeit minimal from our experience. 83 SNPs
showed AAB or ABB genotypes which are only possible in
duplications throughout 198 SNP probe signals in agreement of
the duplication signal with physical size 646 kb. We similarly used
conservative inclusion thresholds to mitigate the false positives from
this array.Parentand sibling sampleswere notcollectedoravailable
to determine if these duplications were inherited but family history
of MDD was reported by all 5 individuals.
We conducted a large scale CNV study on 1,693 MDD cases
and 4,506 controls typed on the Perlegen 600 K platform. This
report represents the first successful CNV analysis using the
Perlegen 600 K platform and the first scan for CNVs contributing
to MDD susceptibility. CNVs were associated to MDD based on
the frequency in cases and exclusivity when compared to controls.
The most significant locus included a 646 kb duplication of SLIT3,
CCDC99, and DOCK2 on 5q35.1 shared by 5 MDD cases. These
results offer a highly penetrant variation which underlies MDD
involving axon structure and guidance, thereby extending previous
observations involving neurotransmitter actions as the underlying
cause of MDD.
Table 2. SNP genotype similarity of 5 individuals with 5q35.1
duplication to prove unrelatedness.
ID1 ID2 PI HAT
05D01518 06D02197 0
05D01518 06D06042 0.01477
05D01518 06D06073 0.01027
05D01518 06D11362 0
06D02197 06D06042 0
06D02197 06D06073 0
06D02197 06D11362 0
06D06042 06D06073 0.0225
06D06042 06D11362 0.02282
06D06073 06D11362 0
Pairwise identity by descent (IBD) comparisons of 5 5q35.1 duplication MDD
cases.
doi:10.1371/journal.pone.0015463.t002
Figure 4. Eigenstrat Principle Components Analysis. The distribution of the second principle component is plotted versus the third principle
component. The overall Caucasian population is shown to be homogenous to avoid spurious results arising from population stratification. The five
cases with 5q35.1 are shown in red to show that they are representative of the overall population and not in any way outliers.
doi:10.1371/journal.pone.0015463.g004
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Ethics Statement
This research was approved by the institutional review board or
the Children’s Hospital of Philadelphia. Informed consent from
the participants was obtained and data were analyzed with
anonymous encrypted labels. Written consent was given by the
patients for their information to be stored in the hospital database
and used for research.
Case:Control Data
Raw genotyping data from three Genetic Association Informa-
tion Network (GAIN) [14] projects typed on the Perlegen 600 K
(Perlegen Sciences Mountain View, CA, USA) array were accessed
through dbGaP. MDD cases and controls who were at low liability
for MDD were utilized from the case:control project ‘‘Major
Depression: Stage 1 Genomewide Association in Population-Based
Samples (phs000020.v2.p1)’’. Psoriasis Cases and Controls were
used to supplement our Perlegen 600 K control cohort for MDD
‘‘Collaborative Association Study of Psoriasis (phs000019.v1.p1)’’.
Lastly, parents from parent-offspring trios were used to further
supplement the control from ‘‘International Multi-Center ADHD
Genetics Project (phs000016.v2.p2)’’. Parents from the ADHD
study were used to maximize the number of unrelated individuals
that could be leveraged for optimal study power.
Case selection
MDD cases were recruited through mental health care
organizations, general practices and in the community setting as
previously described [15].The inclusion criteriafor the 1,780 (1,693
of which were used in this study) participants are: 1) a DSM-IV
diagnosis of major depressive disorder as confirmed by the CIDI
psychiatric interview, 2) an age between 18 through 65 years, 3)
sufficientknowledgeofthe Dutch language,and 4) North-European
ancestry. As the samples should be representative of patients seen in
different settings, there are few a priori exclusion criteria. Excluded
patients are: 1) those with a primary diagnosis of psychosis, bipolar
disorder, obsessive compulsive disorder, severe addiction disorder
and 2) those with insufficient knowledge of the Dutch language.
Control selection
Control subjects matched for age and gender were mainly
derived from the Netherlands Twin Register, for which data
collection in twins, their parents, spouses and siblings occurred in
1991, 1993, 1995, 1997, 2000, 2002/3 and 2004/5. A total of 1860
(1,697 of which were used in this study) controls were selected (only
one member from each family) with the following inclusion criteria:
1) age 18 through 65 years, 2) never scoring high (.0.65) on a
general factor score for anxious depression (a combined measure of
neuroticism, anxiety and depressive symptoms via questionnaires
[15]), 3) never reported a history of MDD in any survey, and 4)
North-European ancestry. Controls and their parents were born in
the Netherlands or northwestern Europe.
Additional control subjects were obtained from two other studies
both ofwhichwereunrelatedtoMDD. The firstoneincluded a case
control study on psoriasis who were genotyped on the Perlegen
platform and included as controls (n=1,600). The psoriasis cases
were diagnosed by dermatologists and their matched controls had
no history of psoriasis, no family history of psoriasis or other auto-
immune disorders. All subjects were 18 years of age or older. The
second control cohort included parents from the ADHD parent-
offspring trios study who were also genotyped on the Perlegen
platform and included as controls (n=1,209).
Additional controls on the Illumina platform were typed on the
We performed high-throughput genome-wide SNP genotyping
using the InfiniumII HumanHap550 BeadChip technology (Illu-
minaSanDiegoCA),attheCenterforAppliedGenomicsatCHOP.
Subjects were primarily recruited from the Philadelphia region
throughthe Hospital’sHealth CareNetwork,including fourprimary
care clinics and several group practices and outpatient practices that
performed well child visits. Eligibility criteria for this study included
all of the following: (1) disease-free children and parents of these
children in the age range of 0–18 yr of age who had high quality,
genome-wide genotyping data from blood samples (defined in
Supplemental Methods); (2) self-reported ethnic background; and (3)
no serious underlying medical disorder, including but not limited to
neurodevelopmental disorders, cancer, chromosomal abnormalities,
and known metabolic or genetic disorders.
PennCNV-Affy Workflow Adapted to Perelgen 600 K Data
The CNV calling on the Perlegen platform used a highly similar
algorithm to those used on the Illumina arrays, but the signal pre-
processing steps differ. Unlike the Illumina platform, where
normalized signal intensities (Log R Ratio and B Allele Frequency)
can be exported directly from the BeadStudio software, these
signal intensity measures in the Perlegen 600 K platform need to
be calculated from the collection of genotyped samples based on
raw X and Y values. To perform data normalization and signal
extraction from raw final report files generated in genotyping
experiments, we first reformatted data from dbGaP into the
format produced by Affymetrix Power Tools: birdseed.calls.txt,
birdseed.confidences.txt, and quant-norm.pm-only.med-po-
lish.expr.summary.txt. The X and Y values provided in the
sample based report files from dbGaP were reduced to a smaller
range by taking the logarithm base 10. For each SNP marker, we
then relied on the allele-specific signal intensity for the AA, AB and
BB genotypes on all genotyped samples to construct three
canonical genotype clusters in polar coordinates theta and R,
similar to the Illumina clustering generation approach. The ‘‘-conf
2’’ option was included in running generate_affy_geno_cluster.pl
since 1 was coded as the best score. Once the canonical genotype
clusters were constructed, we then transformed the signal intensity
values for each SNP to Log R Ratio (LRR) and B Allele Frequency
(BAF) values using normalize_affy_geno_cluster.pl. For more tech-
nical details, see http://www.openbioinformatics.org/penncnv/
penncnv_tutorial_affy_gw6.html.
To optimize the Hidden Markov Model (HMM), we used the
baseline reference file HH550.hmm and ran ‘‘-train’’ in
PennCNV
10 in three successive batches of thirty. The first training
used the samples with the lowest standard deviation of LRR while
the other two runs, using the file created as a new reference,
included more random representative samples. We also created
definition files providing inter-SNP distance and population b-
allele frequency to further inform CNV calling specifically adapted
to the observed Perlegen data. This allowed for CNV calls to be
made with good quality metric scores in 6,199 out of 8,231
Perlegen 600 K samples available. Although the global standard
deviation of LRR was below 0.2 for the majority (84%) of samples,
the intensity data was notably noisier and often showed a
subpopulation of SNPs unable to differentiate a deletion signal,
perhaps due to PCR saturation during the lab processing.
Nevertheless, the deletion and duplication features were still
detected with confirmation of homozygote and AAB/ABB
genotypes respectively shown for the same SNPs. The SNP level
data underlying each CNV call was reviewed to ensure clean
signal quality (Figure 2). To ensure that each detected CNV was a
true DNA feature and not in any way an artifact of the Perlegen
600 K array used or our bioinformatics manipulations of the data,
Duplication of SLIT3 and Major Depressive Disorder
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reviewed the raw Cartesian plots for underlying SNPs (Figure 3).
CNV quality control criteria
We calculated Quality Control (QC) measures on our Perlegen
600 K GWAS data based on statistical distributions to exclude
poor quality DNA samples and false positive CNVs. The first
threshold is the percentage of attempted SNPs which were
successfully genotyped. Only samples with call rate .98% were
included. The genome wide intensity signal must have as little
noise as possible. Only samples with the standard deviation (SD) of
normalized intensity (LRR) ,0.25 were included. All samples
must have Caucasian ethnicity based on Eigenstrat principle
components analysis of genotypes and all other samples were
excluded. Wave artifacts roughly correlating with GC content
resulting from hybridization bias of low full length DNA quantity
are known to interfere with accurate inference of copy number
variations [16]. Only samples where the GC corrected wave factor
of LRR ranged between 20.02,X,0.02 were accepted. If the
count of CNV calls made by PennCNV exceeds 100, the DNA
quality is usually poor. Thus, only samples with CNV call count
,100 were included. Any duplicate samples (such as monozygotic
twins) had one sample excluded.
Statistical analysis of CNVs
CNV frequency between cases and controls was evaluated at
each SNP using Fisher’s exact test. We only considered loci where
cases in the MDD cohort had the same variation and were not
observed in any of the control subjects. We report statistical local
minimums to narrow the association in reference to a region of
nominal significance including SNPs residing within 1 Mb of each
other. Resulting nominally significant CNVRs were excluded if
they met any of the following criteria: i) residing on telomere or
centromere proximal cytobands; ii) arising in a ‘‘peninsula’’ of
common CNV arising from variation in boundary truncation of
CNV calling; iii) genomic regions with extremes in GC content
which produces hybridization bias; or iv) samples contributing to
multiple CNVRs.
Supporting Information
Table S1 Specific phenotypes of the 5 MDD cases with the
duplication of the SLIT3 locus to evaluate co-morbidities
(DOC)
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